Back

Management and impact of atrial fibrillation in the COVID 19 era; concomitancy of two procoagulant phenomena

27 August 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: COVID-19 and cardiovascular pharmacotherapy Anticoagulants ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Mr Ander Arteagoitia Bolumburu

University Medical Centre of the Johannes Gutenberg University, Mainz (Germany)

4 More presentations in this session

Presentation thumbnail
Effect of prophylactic and therapeutic low molecular weight heparins on mortality in 15,704 COVID-19 patients. A systematic review and a meta-analysis.
Doctor A. Pani (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Antiplatelet therapy and outcome in patients with COVID-19. Results from a multi-center international prospective registry (HOPE-COVID19).
Doctor F. Santoro (Foggia, IT)
Abstract Slides Video
Presentation thumbnail
Early experience utilizing bivalirudin as anticoagulation in extracorporeal membrane oxygen in coronavirus disease 2019
Doctor C. Jones (West Palm Beach, US)
Abstract Slides Video
Presentation thumbnail
Effect of statins on mortality in patients with COVID-19: an updated meta-analysis of 147824 patients
Doctor C. Diaz-Arocutipa (Lima, PE)
Abstract Slides Video

Access the full session

Session thumbnail
COVID-19 and cardiovascular pharmacotherapy

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources